Terry Chrisomalis of Seeking Alpha, the investment analyst site, summarizes that Recently, Pfizer (PFE) released final results from its phase 3 study treating patients with a rare heart disease known as Transthyretin cardiomyopathy (TTR-CM). The results were released...